Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 1892 • ACR Convergence 2024
Early Tumor Necrosis Factor Inhibitor Initiation and Chronic Opioid Use in Individuals with Axial Spondyloarthritis
Eva Petrow¹, Jose Meade Aguilar², Christine Peloquin³, S. Reza Jafarzadeh³, Tuhina Neogi³, Maureen Dubreuil⁴ and Jean Liew³, ¹Boston University/Boston Medical Center, Boston, MA, ²Boston Medical Center, Boston, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Patients with axial spondyloarthritis (axSpA) bear a substantial burden of chronic opioid use despite the availability of effective treatments like tumor necrosis factor inhibitors…
Abstract Number: 0523 • ACR Convergence 2024
Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months
Panagiota Goutakoli¹, Eirini Sevdali¹, Elpida Neofotistou-Themeli¹, Argyro Repa², Nestor Avgoustidis³, Sofia Pitsigavdaki⁴, Eleni Kalogiannaki², George Bertsias⁵, Nikolaos Paschalidis⁶, Panayotis Verginis⁷ and Prodromos Sidiropoulos⁸, ¹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation, Heraklion, Greece, ²University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ³University Hospital, Rheumatology and Clinical Immunology,, Heraklion, Greece, ⁴Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, ⁵Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ⁶Biomedical Research Foundation, Academy of Athens, Athens, Greece, ⁷Medical School, University of Crete, Heraklion, Crete, Greece, ⁸University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece
Background/Purpose: Biomarkers to predict response to tofacitinib or adalimumab are not clinically available. Herein we aimed to characterize peripheral blood immune cell subsets with a…
Abstract Number: 1959 • ACR Convergence 2024
A 3-arm, Randomized, Open-label, Parallel Active Controlled, Multicentre International Study to Compare the Response of Ultrasound-assessed Synovitis to Baricitinib, Alone and Combined with Methotrexate versus Etanercept in Rheumatoid Arthritis Patients
ESPERANZA NAREDO¹, Otto Olivas-Vergara², Pablo E. Borges², Sheila Recuero-Díaz², Fernando Saraiva³, Joana Martinho³, Filipa Costa³, Catarina Tenazinha³, Margarida Monteiro³, Ana Teresa Melo³, Ana Rodriguez-García⁴, Carlos A. Guillén-Astete⁵, Boris A. Blanco-Cáceres⁴, Alina L. Boteanu⁴, Antonio Mera-Varela⁶, Eva Pérez Pampín⁶, Yolanda López Golán⁶, Cristina Campos Fernández⁷, Jorge Juan Fragío Gíl⁷, roxana gonzalez mazarío⁷, Juan José De Agustín⁸, Gustavo Añez Sturchio⁹, Luis Coronel Tarancon⁸, Esther Vicente-rabaneda¹⁰, Santos Castañeda¹⁰, Irene Llorente-Cubas¹⁰, Maria S. Stoenoiu¹¹, NZEUSSEU TOUKAP Adrien¹², Ilaria Padovano¹³, Helene Gouze¹³, Ariane Leboime¹³, Maxime Breban¹⁴, Jaqueline Uson¹⁵, Virginia Villaverde¹⁶, Martina Steiner¹⁷, Cristina Vergara Dangond¹⁷, Maria Beatriz Paredes Romero¹⁷, Santiago Muñoz Fernández¹⁸, Carolina Pérez-García¹⁹, Juan Antonio Meraz-Ostiz¹⁹, Stephanie Finzel²⁰, Anna-Maria Kanne²¹, Aránzazu Mediero²², Carmen Herencia²³, Gabriel Herrero-Beaumont²⁴ and Raquel Largo²², ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ²Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ³Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, ⁴Rheumatology Department. Ramón y Cajal University Hospital, Madrid, Spain, ⁵Rheumatology Department. Ramon y Cajal University Hospital, Madrid, Spain, ⁶Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ⁷Department of Rheumatology. Hospital General Universitario de Valencia, Valencia, Spain, ⁸Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁹Department of Rheumatology. Hospital Arnau de Vilanova, Lleida, Spain, ¹⁰Hospital Universitario de La Princesa, Madrid, Spain, ¹¹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹²Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, ¹³Departement of Rheumatology, Hopital Ambroise Paré, Boulogne-Billancourt, Spain, ¹⁴Departement of Rheumatology, Hopital Ambroise Paré, Departement of Rheumatology, Hopital Ambroise Paré, Spain, ¹⁵Department of Rheumatology, Hospital Universitario de Móstoles. University Rey Juan Carlos, Madrid, Spain, ¹⁶Department of Rheumatology, Hospital Universitario de Móstoles, Madrid, Spain, ¹⁷Department of Rheumatology. Hospital Universitario Infanta Sofía., Madrid, Spain, ¹⁸Hospital Universitario Infanta Sofía. Universidad Europea de Madrid, Madrid, Spain, ¹⁹Department of Rheumatology, Hospital del Mar of Barcelona, Barcelona, Spain, ²⁰Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, DE, Freiburg im Breisgau, Germany, ²¹Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany, ²²Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, Madrid, Spain, ²³Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, M, Spain, ²⁴Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain
Background/Purpose: To demonstrate non-inferiority of the response of musculoskeletal ultrasound (MSKUS)-assessed synovitis to baricitinib, alone and plus MTX vs. etanercept plus MTX in patients with…
Abstract Number: 0586 • ACR Convergence 2024
Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
Alexis Ogdie¹, Xiaolan Ye², Yi Peng³, Christopher Saffore⁴, Jayne Stigler⁵ and Martin Bergman⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶self, Beach Haven, NJ

Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy for the treatment of PsA in randomized controlled trials of patients with inadequate response or…
Abstract Number: 2253 • ACR Convergence 2024
A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB002, an Anti-TNFα mAb Designed for Extended Half-life, in Healthy Volunteers
Cory Sellwood¹, Minggeng Gao², Mark Matijevic², Stephen Wax³, Mason Yamashita², Shan Yu², Sujata Arora² and Rachel Kirk², ¹New Zealand Clinical Research, Christchurch, New Zealand, ²Zenas BioPharma, Waltham, MA, ³Former Employee of Zenas Biopharma, Newton, MA
Background/Purpose: ZB002 is a recombinant human monoclonal antibody (mAb) that targets human TNFα with an Fv domain identical in amino acid sequence to adalimumab and…
Abstract Number: 0595 • ACR Convergence 2024
bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Sélina HANNA ABDELMASSIH¹, Tiphaine DUJARDIN², Athan BAILLET¹, Philippe GAUDIN¹ and Xavier ROMAND¹, ¹Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France, ²Hôpital Reine Hortense, Aix-les-Bains, France
Background/Purpose: During the last two decades we’ve witnessed the rising use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of psoriatic arthritis (PsA), leaving…
Abstract Number: 2269 • ACR Convergence 2024
Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial
Sadaf Atiqi¹, Maike Wientjes², Maureen Leeuw³, Laura Boekel⁴, Femke Hooijberg¹, Floris Loeff⁵, Charlotte Krieckaert¹, Annick De Vries⁵, Michael Nurmohamed⁶, Theo Rispens⁵, Maarten Boers⁷, Bart van den Bemt⁸, Alfons den Broeder² and Gertjan Wolbink⁹, ¹Reade, Amsterdam, Netherlands, ²Sint Maartenskliniek, Ubbergen, Netherlands, ³Reade, Zeist, Netherlands, ⁴Vrije Universiteit Amsterdam, Amsterdam, Netherlands, ⁵Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁶Reade and Amsterdam UMC, Kortenhoef, Netherlands, ⁷Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ⁸Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands, ⁹Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands
Background/Purpose: The latest European and American recommendations support tapering of biological DMARDs (bDMARDs) in patients with persistent remission or low disease activity. Most clinicians use…
Abstract Number: 0059 • ACR Convergence 2024
Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance
Susanna R. Bidgood¹, Sophie Hopkin¹, Kathryn R. Malpas¹, David M. Kallenberg¹, Jacqueline O’Neill¹, Geofrey Odede¹, Bernard Lauwerys², Baran Ufuktepe³ and David Humphreys¹, ¹UCB Biopharma UK, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³UCB Pharma, Istanbul, Turkey
Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels have poorer prognosis, more severe progressive…
Abstract Number: 0596 • ACR Convergence 2024
Impact of a Multidisciplinary Rheumatology-Dermatology-Gastroenterology Center in the Management of Patients with Psoriatic Arthritis: Analysis of the First 5-years of Implementation
Marina Sánchez-Lucas¹, Camille Bourgeois¹, Juan Molina-Collada², Teresa Gonzalez-Hernandez¹, Juan Carlos Nieto Gonzalez¹, Amparo Lopez-Esteban¹, Ofelia Baniandres¹, Esther Chamorro de Vega¹ and Isabel Castrejon³, ¹Hospital Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Psoriatic arthritis (PsA) has a heterogenous clinical phenotype with manifestations in a number of different organs and systems. These include not only enthesitis, synovitis…
Abstract Number: 2278 • ACR Convergence 2024
Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study
Olga Tsyruk¹, Marina Birck², Sasha Bernatsky², Luck Lukusa³, Denis Choquette⁴, Gilles Boire⁵ and Walter Maksymowych⁶, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Rhumadata™, Montreal, QC, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment adherence is crucial to optimizing outcomes in rheumatic diseases. Suboptimal adherence is common with inflammatory and chronic diseases, often treated with biologics, including…
Abstract Number: 0131 • ACR Convergence 2024
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study
Carol Hitchon¹, Dawn Bowdish², Gilles Boire³, Paul Fortin⁴, Louis Flamand⁵, Vinod Chandran⁶, Roya M Dayam⁷, Anne-Claude Gingras⁸, Catherine Card⁹, Ines Colmegna¹⁰, Maggie Larche², Gil Kaplan¹¹, Luck Lukusa¹², Jennifer Lee¹² and Sasha Bernatsky¹³, and SUCCEED investigative team, ¹University of Manitoba, Winnipeg, MB, Canada, ²McMaster University, Hamilton, ON, Canada, ³Retired, Sherbrooke, QC, Canada, ⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁵Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, ⁶University of Toronto, Toronto, ON, Canada, ⁷Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada, ⁸Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, ⁹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada, ¹⁰The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹University of Calgary, Calgary, AB, Canada, ¹²The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Given ongoing SARS-CoV-2 circulation, COVID-19 vaccination response in immune-mediated inflammatory disease (IMID) remains a key issue, particularly regarding effects of common immunosuppressives like methotrexate…
Abstract Number: 0603 • ACR Convergence 2024
Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
Jakub Závada¹, Jana Baranová², Karel Pavelka¹, Jiří Vencovský³, Pavel Horak⁴, Kateřina Kusalová² and Ladislav Šenolt³, and collaborators of the ATTRA registry, ¹Institute of Rheumatology and Charles University, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic
Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
Abstract Number: 2279 • ACR Convergence 2024
Discontinuation Pattern of Glucocorticoids in Patients with Rheumatoid Arthritis Initiating Biologics or Targeted Synthetic DMARDs in Routine Care
Isabel Castrejon¹, Lucia Otero-Varela², José María Álvaro-Gracia³, Jerusalem Calvo Gutierrez⁴, Cristina Campos-Fernández⁵, Alicia García Dorta⁶, Ana Perez⁷, DOLORES RUIZ MONTESINO⁸ and Fernando Sánchez-Alonso⁹, and on behalf of BIOBADASER, ¹Hospital General Universitario Gregorio Marañon, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Gregorio Marañón, Madrid, Spain, ⁴HU Reina Sofia, Cordoba, Spain, ⁵Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ⁶Rheumatologist, La Laguna, Spain, ⁷Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ⁸Hospital Virgen Macarena, Sevilla, Spain, ⁹Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: Glucocorticoids (GC) have a rapid effect on symptoms, but chronic exposure is associated to important adverse events. Although both EULAR and ACR guidelines (1,2),…
Abstract Number: 0146 • ACR Convergence 2024
Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions
Bashar Tanous¹, SRIKAR SAMA², Nidaa Rasheed³ and Candice Reyes⁴, ¹UCSF Fresno, Fresno, ²University of California San Francisco Fresno, Fresno, CA, ³UCSF Fresno, Fresno, CA, ⁴VACCHCS, Fresno, CA
Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
Abstract Number: 0806 • ACR Convergence 2024
Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St-Pierre⁴, Olga Basso¹, Anick Bérard⁵ and Evelyne Vinet³, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Université de Montréal, Montreal, QC, Canada
Background/Purpose: Until recently, best practice guidelines recommended withholding rotavirus vaccine in offspring exposed in utero to any TNFi until 6 months of age due to fears of…

« Previous Page
1
…
3
4
5
6
7
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].